Sucampo Pharmaceuticals (SCMP) : Average target price received by Sucampo Pharmaceuticals (SCMP) is $19.14 with an expected standard deviation of $6.87. The most aggressive target on the stock is $29, whereas the most downbeat target is $13. 7 financial analysts are currently covering the stock.
Sucampo Pharmaceuticals (SCMP) : The consensus on Sucampo Pharmaceuticals (SCMP) based on 7 analyst recommendation on the company stock is 1.86, which is interpreted as a Buy recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 3 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating.
Also, Major Brokerage house, Mizuho Securities downgrades its ratings on Sucampo Pharmaceuticals (NASDAQ:SCMP). According to the latest information available, the shares are now rated Neutral by the analysts at the agency. Previously, the analysts had a Buy rating on the shares. The rating by the firm was issued on August 4, 2016.
Sucampo Pharmaceuticals (NASDAQ:SCMP): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $10.94 and $10.83 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $11.11. The buying momentum continued till the end and the stock did not give up its gains. It closed at $11.10, notching a gain of 1.28% for the day. The total traded volume was 221,025 . The stock had closed at $10.96 on the previous day.
Sucampo Pharmaceuticals, Inc. is a global biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic, and oncology-based inflammatory disorders. It generates revenue from product royalties, development milestone payments, product sales and clinical development activities. Its operations are conducted through Sucampo AG (SAG), based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Bethesda, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, United Kingdom. The Companys geographic segments are Asia, the Americas and Europe.